- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07432958
En studie for å evaluere effektiviteten av to doser AP-472 som tilleggsterapi til levodopa hos deltakere med Parkinsons sykdom (PD) med motoriske fluktuasjoner
Fase 2, dobbeltblind, placebokontrollert studie for å evaluere effektiviteten av to doser av AP-472 som tilføyelsesterapi til levodopa hos deltakere med Parkinsons sykdom (PD) med motoriske fluktuasjoner
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.
The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given.
The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Annie Blobaum, Ph.D.
- Telefonnummer: 615-427-1935
- E-post: annie@appellopharma.com
Studiesteder
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205-5551
- Rekruttering
- University of Arkansas for Medical Sciences (Site #208)
-
-
California
-
Carlsbad, California, Forente stater, 92011
- Rekruttering
- Profound Research LLC (Site #222)
-
Los Alamitos, California, Forente stater, 90720-3108
- Rekruttering
- Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS (Site #217)
-
Los Angeles, California, Forente stater, 90033-5310
- Rekruttering
- Keck Medicine of USC - USC Healthcare Center 2 (Site #221)
-
Palo Alto, California, Forente stater, 94301
- Rekruttering
- Parkinson's Research Centers of America (Site #218)
-
-
Colorado
-
Englewood, Colorado, Forente stater, 80113-2776
- Rekruttering
- Rocky Mountain Clinical Research - CenExel - PPDS (Site #215)
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33486
- Rekruttering
- Parkinson's Disease & Movement Disorders Center of Boca Raton (Site #227)
-
Boca Raton, Florida, Forente stater, 33486
- Rekruttering
- UM-UHealth at Boca Raton (Site #226)
-
Hallandale, Florida, Forente stater, 33009
- Rekruttering
- Velocity Clinical Research - Hallandale Beach (Site #228)
-
Miami, Florida, Forente stater, 33136-1051
- Rekruttering
- University of Miami (Site #220)
-
Orlando, Florida, Forente stater, 32825
- Rekruttering
- Neurology One (Site #205)
-
Tampa, Florida, Forente stater, 33613-4808
- Rekruttering
- USF Parkinson's Disease and Movement Disorders Center (Site #206)
-
-
Georgia
-
Augusta, Georgia, Forente stater, 30912-0020
- Rekruttering
- Augusta University Medical Center (Site #212)
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46256
- Rekruttering
- Josephson Wallack Munshower Neurology PC (Site #231)
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- Rekruttering
- The University of Kansas (KU) (Site #216)
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536-0001
- Rekruttering
- Kentucky Neuroscience Institute (Site #213)
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215-5400
- Rekruttering
- Beth Israel Deaconess Medical Center (Site #211)
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan Health System (UMHS) (Site #202)
-
Farmington Hills, Michigan, Forente stater, 48334-2973
- Rekruttering
- Quest Research Institute - Alcanza - PPDS (Site #201)
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87106
- Rekruttering
- University of New Mexico Health Sciences Center (Site #225)
-
-
New York
-
New York, New York, Forente stater, 10029-6501
- Rekruttering
- Mount Sinai School of Medicine (Site #209)
-
New York, New York, Forente stater, 10021
- Rekruttering
- Joan and Sanford I. Weill Department of Medicine (Site #224)
-
-
North Carolina
-
Asheville, North Carolina, Forente stater, 28806
- Rekruttering
- Asheville Neurology Specialists, P.A. (Site #229)
-
Durham, North Carolina, Forente stater, 27705
- Rekruttering
- Duke Neurological Disorders Clinic (Site #210)
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195-0001
- Rekruttering
- Cleveland Clinic (Site #223)
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- The Ohio State University Wexner Medical Center (site #207)
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Rekruttering
- Vanderbilt University Medical Center (Site #204)
-
-
Texas
-
Cypress, Texas, Forente stater, 77429
- Rekruttering
- Horizon Clinical Research: Gill Neuroscience - Houston (Site #232)
-
Round Rock, Texas, Forente stater, 78681-3578
- Rekruttering
- Central Texas Neurology Consultants (Site #203)
-
-
Washington
-
Kirkland, Washington, Forente stater, 98034-3013
- Rekruttering
- EvergreenHealth (Site #219)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
Participants must meet all of the following criteria to take part in the study:
- Be a man or woman between 30 and 80 years of age at the time of screening.
- Have a diagnosis of Parkinson's disease, confirmed using standard medical criteria, including slowness of movement and symptoms that affect one side of the body more than the other.
- Have mild to moderate Parkinson's disease, defined as stage 3 or lower on the Hoehn and Yahr scale when medications are working ("ON" state).
- Experience an average of at least 3 hours of OFF time per day, based on home symptom diaries, with at least 2.5 hours of OFF time each day during the baseline period.
- Have a Montreal Cognitive Assessment (MoCA) score of 24 or higher at screening.
- Be able to walk independently, with or without the use of a walking aid.
- Be able to swallow oral medication.
- Have been on a stable Parkinson's medication regimen for at least 4 weeks before screening. Medications known as MAO-B inhibitors must have been stable for at least 12 weeks.
- Be taking levodopa at least four times daily (immediate- or controlled-release formulations) or three times daily (extended-release formulations such as Rytary or Crexont).
Key Exclusion Criteria:
Participants cannot take part in the study if any of the following apply:
- Have a form of parkinsonism that is not typical Parkinson's disease, such as secondary or atypical parkinsonism.
- Have previously received, or plan to receive during the study, advanced Parkinson's therapies such as continuous levodopa or dopamine delivery systems, or Parkinson's disease-related brain surgery.
- Have dyskinesias (involuntary movements) that are severe enough, in the study doctor's opinion, to interfere with participation.
- Have a history of only certain types of dyskinesias (such as OFF-state, diphasic, myoclonic, or dystonic dyskinesias) without typical peak-dose dyskinesias.
- Are currently taking medications that block dopamine, except for low-dose quetiapine (up to 50 mg per day) used for insomnia.
- Routinely use on-demand "rescue" Parkinson's medications more than three times per week.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Oral tablet |
|
Eksperimentell: Low Dose
AP-472 100 mg per day |
Oral tablet Oral tablet |
|
Eksperimentell: High Dose
AP-472 300 mg per day |
Oral tablet |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Endring fra baseline i gjennomsnittlig daglig OFF-tid på motordagbøker for AP-472 sammenlignet med placebo (normalisert til 16 timers våken tid)
Tidsramme: Uke 12
|
Uke 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Endring fra utgangspunkt i ON-tid uten plagsom dyskinesi (normalisert til 16 timer)
Tidsramme: Uke 12
|
Uke 12
|
|
|
Change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 2 (Motor Experiences of Daily Living (M-EDL)) score
Tidsramme: Week 12
|
For MDS-UPDRS Part II (Motor Experiences of Daily Living, M-EDL) there are 13 items each scored from 0 to 4. The total score range is from 0-52. A higher score indicates worse motor impact on daily activities; lower scores are better. |
Week 12
|
|
Change from baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) summary index
Tidsramme: Week 12
|
For the Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index the score is calculated by averaging the 8 domain scores and converting them to a 0-100 scale. A higher score indicates worse health-related quality of life; lower scores are better. |
Week 12
|
|
Change from baseline in MDS-UPDRS Part III (Motor Examination) score in the best ON state
Tidsramme: Week 12
|
The MDS-UPDRS Part III includes 33 items, each scored from 0 to 4. The total score range is from 0-132. A higher score indicates worse motor impairment; lower scores are better. |
Week 12
|
|
Change from baseline in Epworth Sleepiness Scale (ESS) total score
Tidsramme: Week 12
|
The ESS consists of 8 items, each scored from 0 to 3. The total score range is from 0-24. Higher scores indicate greater daytime sleepiness; lower scores are better. |
Week 12
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Synukleinopatier
- Nevrologiske manifestasjoner
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Nevrodegenerative sykdommer
- Bevegelsesforstyrrelser
- Parkinsonlidelser
- Basal ganglia sykdommer
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Dyskinesier
- Parkinsons sykdom
Andre studie-ID-numre
- APLO-1201
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .